LMAT

$112.23

Pre-MarketAs of Mar 17, 8:00 PM UTC

LeMaitre Vascular, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$112.23
Potential Downside
52.3%
Whystock Fair Value$53.53
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreser...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
44.36
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Strong income play. Yield provides a meaningful total return floor.
89.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
15.80%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
10.81

Recent News

StockStory
Mar 16, 2026

3 Cash-Producing Stocks with Warning Signs

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 13, 2026

3 Healthcare Stocks We’re Skeptical Of

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 3.8%, nearly mirrorring the S&P 500.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 5, 2026

2 Profitable Stocks with Exciting Potential and 1 We Turn Down

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 2, 2026

LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 2, 2026

LeMaitre Vascular (LMAT) Is Up 16.4% After Dividend Hike And Buyback Plan – Has The Bull Case Changed?

In late February 2026, LeMaitre Vascular reported higher fourth-quarter and full-year 2025 sales and earnings, raised its quarterly dividend to US$0.25 per share, issued upbeat 2026 guidance, and authorized a new US$100 million share repurchase program running through February 18, 2027. Together, the stronger results, higher capital returns, and confident outlook highlight management’s emphasis on balancing business expansion with returning cash to shareholders. Next, we’ll explore how the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.